Innovent Biologics Presents Positive Phase I Results for IBI343 at ESMO GI Congress 2024
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...
HKG: 1801
Innovent Biologics’ Mazdutide Shows Promise in Phase III Obesity Trial
Innovent Biologics Inc. (HKG: 1801), a biopharmaceutical company based in China, has announced the presentation...
Innovent Biologics’ IBI363 Shows Promising Results in Phase Ia/Ib Trial for Advanced Solid Tumors
Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...
Innovent Biologics’ CLDN18.2-Targeted ADC IBI343 Earns FDA Fast-Track Status
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Innovent Biologics Presents Clinical Data for Pipeline Candidates at ASCO 2024
Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, presented updates on several...
Innovent Biologics’ Picankibart Achieves Positive Results in Phase III Psoriasis Trial
Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced the successful...
Innovent Biologics’ Picankibart Achieves Positive Results in Phase III Psoriasis Trial
Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced the successful...
Innovent Biologics’ IBI311 New Drug Application Accepted for Review by China’s CDE
Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...
Innovent Biologics’ Mazdutide Shows Superiority in Type 2 Diabetes Phase III Trial
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Innovent Biologics’ CLDN18.2 ADC IBI343 Receives Breakthrough Designation in China
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Innovent Biologics’ Pemazyre Wins Macau Approval for Cholangiocarcinoma Treatment
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has received marketing approval...
Innovent Biologics’ IBI133 Receives Tacit Approval for Clinical Trial from China’s CDE
The Center for Drug Evaluation (CDE) in China has granted tacit clinical trial approval to...
Innovent Biologics Initiates Phase III Neoshot Study for MSI-H/dMMR Colon Cancer Treatment
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...
Innovent Biologics Reports 36.2% Revenue Growth in 2023, Highlights Robust Product Sales
Innovent Biologics Inc. (HKG: 1801), a China-based biotechnology firm, has released its 2023 financial report,...
Innovent Biologics Denies Lab Closure, Confirms Relocation to California
Innovent Biologics (HKG: 1801) has refuted unconfirmed reports regarding the closure of its Rockville, Maryland...
Innovent Biologics Allegedly Closes US Research Facility, Shifts Focus to China
Innovent Biologics (HKG: 1801), a China-based biotech firm, has reportedly closed down a research team...
Innovent and HutchMed’s Combination Therapy Set for Priority Review in China for Advanced Endometrial Cancer
China’s Center for Drug Evaluation (CDE) has indicated that the combination therapy of Innovent Biologics...
Innovent Biologics’ Taletrectinib Receives Second NDA Acceptance in China for ROS1 Positive NSCLC
Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced that the...
Innovent Biologics Launches Phase I Study for IBI3002, a Bispecific Antibody Targeting Asthma
Innovent Biologics, Inc. (HKG: 1801), based in China, has announced the initiation of its Phase...
Innovent Biologics’ Tyvyt Receives Marketing Approval for Multiple Indications in Macau
Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...